Abiopharma

🔍 TYNDALL JOSEPH A. (Director)

Company: Axogen, Inc. (AXGN)

Report Date: 2026-06-19

Detailed Transactions and Holdings:

• Acquired 14,150 shares of Common Stock (Direct)
  Date: 2026-06-19 | Code: M | equity_swap_involved: 0 | shares_owned_after: 14,150.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 14,150 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-19 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F3, F3

Footnotes:

• F1: This reflects the number of restricted stock units that vested June 19, 2026.
• F2: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
• F3: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.